vs

Side-by-side financial comparison of Enact Holdings, Inc. (ACT) and Kiniksa Pharmaceuticals International, plc (KNSA). Click either name above to swap in a different company.

Enact Holdings, Inc. is the larger business by last-quarter revenue ($312.7M vs $202.1M, roughly 1.5× Kiniksa Pharmaceuticals International, plc). On growth, Kiniksa Pharmaceuticals International, plc posted the faster year-over-year revenue change (65.0% vs 3.6%). Over the past eight quarters, Kiniksa Pharmaceuticals International, plc's revenue compounded faster (59.1% CAGR vs 3.6%).

Enact Holdings, Inc. is a leading U.S.-based private mortgage insurance provider. It delivers risk mitigation solutions to residential mortgage lenders, banks, and credit unions, enabling borrowers with smaller down payments to access affordable home financing, and supports sustainable homeownership for diverse consumer groups across the United States.

Kiniksa Pharmaceuticals International plc is a global biopharmaceutical firm focused on discovering, developing and commercializing targeted therapies for patients with unmet medical needs, primarily in autoimmune, inflammatory and rare disease segments. It operates across major markets including North America, Europe and Asia, advancing a pipeline of clinical-stage and approved treatment candidates.

ACT vs KNSA — Head-to-Head

Bigger by revenue
ACT
ACT
1.5× larger
ACT
$312.7M
$202.1M
KNSA
Growing faster (revenue YoY)
KNSA
KNSA
+61.3% gap
KNSA
65.0%
3.6%
ACT
Faster 2-yr revenue CAGR
KNSA
KNSA
Annualised
KNSA
59.1%
3.6%
ACT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACT
ACT
KNSA
KNSA
Revenue
$312.7M
$202.1M
Net Profit
$14.2M
Gross Margin
89.6%
Operating Margin
71.3%
9.8%
Net Margin
7.0%
Revenue YoY
3.6%
65.0%
Net Profit YoY
259.8%
EPS (diluted)
$1.23
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACT
ACT
KNSA
KNSA
Q4 25
$312.7M
$202.1M
Q3 25
$311.5M
$180.9M
Q2 25
$304.9M
$156.8M
Q1 25
$306.8M
$137.8M
Q4 24
$301.8M
$122.5M
Q3 24
$309.6M
$112.2M
Q2 24
$298.8M
$108.6M
Q1 24
$291.6M
$79.9M
Net Profit
ACT
ACT
KNSA
KNSA
Q4 25
$14.2M
Q3 25
$18.4M
Q2 25
$17.8M
Q1 25
$8.5M
Q4 24
$-8.9M
Q3 24
$-12.7M
Q2 24
$-3.9M
Q1 24
$-17.7M
Gross Margin
ACT
ACT
KNSA
KNSA
Q4 25
89.6%
Q3 25
88.8%
Q2 25
88.1%
Q1 25
87.0%
Q4 24
85.4%
Q3 24
82.1%
Q2 24
88.7%
Q1 24
86.7%
Operating Margin
ACT
ACT
KNSA
KNSA
Q4 25
71.3%
9.8%
Q3 25
67.4%
13.3%
Q2 25
70.4%
12.9%
Q1 25
68.9%
9.6%
Q4 24
68.9%
-15.7%
Q3 24
74.1%
-8.6%
Q2 24
78.6%
-0.1%
Q1 24
70.6%
-20.7%
Net Margin
ACT
ACT
KNSA
KNSA
Q4 25
7.0%
Q3 25
10.2%
Q2 25
11.4%
Q1 25
6.2%
Q4 24
-7.3%
Q3 24
-11.3%
Q2 24
-3.6%
Q1 24
-22.2%
EPS (diluted)
ACT
ACT
KNSA
KNSA
Q4 25
$1.23
$0.18
Q3 25
$1.10
$0.23
Q2 25
$1.11
$0.23
Q1 25
$1.08
$0.11
Q4 24
$1.05
$-0.11
Q3 24
$1.15
$-0.18
Q2 24
$1.16
$-0.06
Q1 24
$1.01
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACT
ACT
KNSA
KNSA
Cash + ST InvestmentsLiquidity on hand
$582.5M
$414.1M
Total DebtLower is stronger
$744.5M
Stockholders' EquityBook value
$5.4B
$567.6M
Total Assets
$6.9B
$763.6M
Debt / EquityLower = less leverage
0.14×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACT
ACT
KNSA
KNSA
Q4 25
$582.5M
$414.1M
Q3 25
$545.6M
$352.1M
Q2 25
$616.0M
$307.8M
Q1 25
$639.0M
$268.3M
Q4 24
$602.8M
$243.6M
Q3 24
$674.9M
$223.8M
Q2 24
$711.3M
$218.8M
Q1 24
$624.3M
$213.6M
Total Debt
ACT
ACT
KNSA
KNSA
Q4 25
$744.5M
Q3 25
$744.1M
Q2 25
$743.8M
Q1 25
$743.4M
Q4 24
$743.0M
Q3 24
$742.7M
Q2 24
$742.4M
Q1 24
$746.1M
Stockholders' Equity
ACT
ACT
KNSA
KNSA
Q4 25
$5.4B
$567.6M
Q3 25
$5.3B
$535.4M
Q2 25
$5.2B
$495.0M
Q1 25
$5.1B
$457.5M
Q4 24
$5.0B
$438.4M
Q3 24
$5.0B
$437.0M
Q2 24
$4.8B
$435.1M
Q1 24
$4.7B
$431.9M
Total Assets
ACT
ACT
KNSA
KNSA
Q4 25
$6.9B
$763.6M
Q3 25
$6.9B
$712.3M
Q2 25
$6.8B
$661.1M
Q1 25
$6.7B
$599.3M
Q4 24
$6.5B
$580.6M
Q3 24
$6.6B
$555.3M
Q2 24
$6.3B
$542.4M
Q1 24
$6.3B
$519.7M
Debt / Equity
ACT
ACT
KNSA
KNSA
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.14×
Q1 25
0.15×
Q4 24
0.15×
Q3 24
0.15×
Q2 24
0.15×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACT
ACT
KNSA
KNSA
Operating Cash FlowLast quarter
$724.5M
$53.9M
Free Cash FlowOCF − Capex
$53.3M
FCF MarginFCF / Revenue
26.4%
Capex IntensityCapex / Revenue
0.3%
Cash ConversionOCF / Net Profit
3.80×
TTM Free Cash FlowTrailing 4 quarters
$136.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACT
ACT
KNSA
KNSA
Q4 25
$724.5M
$53.9M
Q3 25
$192.0M
$33.7M
Q2 25
$119.5M
$28.1M
Q1 25
$226.7M
$22.3M
Q4 24
$686.3M
$18.8M
Q3 24
$188.1M
$-2.2M
Q2 24
$144.7M
$5.2M
Q1 24
$187.3M
$4.0M
Free Cash Flow
ACT
ACT
KNSA
KNSA
Q4 25
$53.3M
Q3 25
$33.0M
Q2 25
$27.9M
Q1 25
$22.2M
Q4 24
$18.6M
Q3 24
Q2 24
Q1 24
$3.9M
FCF Margin
ACT
ACT
KNSA
KNSA
Q4 25
26.4%
Q3 25
18.2%
Q2 25
17.8%
Q1 25
16.1%
Q4 24
15.2%
Q3 24
Q2 24
Q1 24
4.9%
Capex Intensity
ACT
ACT
KNSA
KNSA
Q4 25
0.3%
Q3 25
0.4%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.2%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
ACT
ACT
KNSA
KNSA
Q4 25
3.80×
Q3 25
1.83×
Q2 25
1.58×
Q1 25
2.61×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons